Silverback Therapeutics

Biotechnology ResearchWashington, United States51-200 Employees

Silverback Therapeutics is a clinical-stage biotechnology company based in Seattle, Washington, that focuses on developing systemically delivered, tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. Its ImmunoTAC platform enables the pairing of linker-payloads with monoclonal antibodies directed to specific disease sites, aiming to modulate key disease-modifying pathways and direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. The company serves the oncology and infectious disease spaces, addressing the need for targeted immuno-oncology approaches that concentrate therapeutic activity at diseased tissues while aiming to minimize systemic effects. Silverback operates in the biotechnology research industry, positioned as a developer of a new class of targeted immuno-oncology agents and related therapeutics. The organization is headquartered in Seattle, and, as a clinical-stage company, operates with a workforce typical of a mid-sized biopharma enterprise. A recent development noted is a partnership activity related to its merger context with ARS Pharmaceuticals, reflecting ongoing strategic collaborations in its broader corporate trajectory.

Sign up for free to view info

Email Format Employee directory